cyrilzakka/clinical-trials huggingface dataset:
EXPRE-SON-REA : Expressive Own Names in Neurophysiologic Assessment of Comatose Patients

Evaluating the neurologic prognosis in disorders of consciousness (DOC) patients is still a crucial issue in intensive care units.

Neurophysiology allows the investigators to record cerebral responses of patients to auditory stimuli and in particularly to their own name. Numerous studies try to improve the relevance of the auditory stimuli used in this paradigm.

Here the investigators assess if the use of own name stimuli uttered by more expressive voices (for example smiling voices) modulates the cerebral responses recorded. They then correlate these cerebral responses to the neurologic prognosis at three months.

Late auditory evoked potentials (as P3 wave) are used in neurophysiology to assess the level of consciousness in DOC (disorder of consciousness) patients. The P3 wave, elicited by listening standard and deviant stimuli, corresponds to the activation of a frontoparietal network and is considered to reflect a cognitive attention task. Using the own name of the patient as deviant stimuli improve the ability to detect the P3 wave because of the particularly relevance of this stimulus for the patient. However the correlation of this P3 wave and neurologic prognosis is still imperfect and depends on the etiology of the DOC.

In human cognition, to identify the expressivity valence of a voice is essential. Neural processing of expressive voices involves more widespread brain areas than neutral voices processing.

Here the investigators assume that using own name stimuli uttered by more expressive voices (positive : smiling voice or negative : rough voice) should recruit more widespread brain areas and modulate the cerebral responses recorded. The investigators then evaluate if these cerebral responses are relevant markers of consciousness and correlate them to neurologic prognosis at three months.

Eligibility Criteria:
Inclusion Criteria:

* Age over 18
* Disorder of consciousness defined as :

Glasgow coma scale \< 8 or \>8 but

* eyes opening to pain only
* No response to basic command
* Available neuro-imagery (CT-scan or MRI)
* Normal temperature (no fever or hypothermia)
* Normal blood pressure during neurophysiologic evaluation
* Given consent from relatives

Exclusion Criteria:

* Brain death
* Known deafness
* Severe sepsis uncontrolled during neurophysiologic evaluation
Study on Neuropsychiatric Behavior in Cadmium-exposed People

This study hypothesized that excessive cadmium is related to clinical pain, depression, and cognitive impairment, and that related indicators will improve after cadmium is eliminated.

This study will combine the research progress of the innovative drug GMDTC, the mechanism of nerve damage caused by Cd2+ disrupting Ca2+ homeostasis, imaging technology and analysis methods, and the basis of our previous research work to explore the effect of the chemical Class 1 innovative drug GMDTC on the neuropsychiatric behavior of people with excessive cadmium. mechanism of action. This study is not limited to the study of the mechanism of neurotoxicity after Cd2+ deposition. It will also clarify the clinical efficacy of the innovative drug GMDTC in removing Cd2+ deposition in the brain and reducing damage, which is expected to open up new avenues for the treatment of cadmium neurotoxicity. This study hypothesized that excessive cadmium is related to clinical pain, depression, and cognitive impairment, and that related indicators will improve after cadmium is eliminated.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years old, both men and women are welcome
* The weight of male subjects is ≥50.0 kg, the weight of female subjects is ≥45.0 kg, and the body mass index (BMI) is between 19 \~ 26 kg/m2, including the critical value
* Urinary cadmium \&gt;5 μmol/mol creatinine for 2 consecutive days (creatinine content is ≥0.3 μg/L and ≤3 μg/L)
* Right-handed
* Voluntarily participate in this study and sign informed consent.

Exclusion Criteria:

* Combined with other neurodevelopmental problems (such as autism), organic brain mental disorders (such as Alzheimer\&#39;s disease, Parkinson\&#39;s disease, etc.) and organic brain diseases (such as cerebral hemorrhage, infarction, etc.) that meet the DSM-5 diagnostic criteria )
* Those who have suffered from or are currently suffering from any serious clinical diseases that pose safety risks such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities
* Continuous use of high-dose neuroleptics in the past 3 months (high-dose: daily dosage of benzodiazepines ≥ 4 mg lorazepam equivalent; long-term: the total duration of use is at least 60 days)
* Have contraindications for MRI or bone density examination (pacemaker or defibrillator, artificial heart valve, clothing containing fluorescein, iron, etc.)
* Pregnant and lactating women
* Those who cannot tolerate venipuncture and/or have a history of fainting from blood or needles
* Those with eGFR \<30 mL/min/1.73 m2 during screening (eGFR is calculated using the Cockcroft-Gault formula: eGFR(mL/min/1.73m2) = (140-age)\*weight (kg)/\[0.818\*Cr(μmol/L )\]\*0.85(female))
Lornoxicam Versus Etodolac After Third Molar Surgery

Our study aimed to compare the effect of lornoxicam and etodolac on postoperative pain, edema and trismus following lower third molar extraction

20 patients included in study (4 male, 16 female). Lornoxicam and etodolac was given following lower third molar extraction. Pain was evaluated 2., 6., 12., 24., and 48. hours using VAS. Edema was evaluated by measuring tragus-labial commissure, angulus- lateral canthus of eye and angulus mandible-labial commissure. Trismus was evaluated measuring mouth opening by caliper. Edema and Trismus was evaluated by 48. and 168. hours

Eligibility Criteria:
Inclusion Criteria:

* Bilateral mesioangular impacted lower third molar
* Asymptomatic Third Molar (No history of infection)
* Systemically Healthy Person
* Person Between aged 18-30

Exclusion Criteria:

* People who are pregnant and lactation process
* People who had any systemic disease
* People who are gastrointestinal problems
* People who are sensitive to drugs used in study
* Lower Third Molar associated with cysts and infections
Prevalence of Obesity and Overweight in Primary School Children in the Rhein-Neckar Region in Germany

The study will determine the weight status in primary school children in the Rhein-Neckar Region in Germany and will analyse the development of height and weight in these children during the time of COVID-19 related restrictions by asking parents to provide data from childhood examinations. Additionally, interactions between cognitive abilities and weight-status will be studied.

The prevalence of obesity and overweight is increasing among both adults and children. School and kindergarten closings during the COVID-19 epidemic may have had an additional negative impact on the weight development of the affected children. This study aims to examine the post-lockdown prevalence of overweight and obesity in school children in the second grade in the Rhein-Neckar Region in Germany and look at possible lockdown effects. Additionally, interactions between cognitive abilities and weight-status will be studied.

Anthropometric measurements, interviews as well as cognitive testing will be performed in schools in the summer of 2021 in children in the first grade (class 2020/2021). Parents will be asked to provide measurements from U-childhood-examinations and complete a 3-day food record. The local health authority (Gesundheitsamt) will assist in making a representative selection of schools from different socioeconomic areas and provide data from the pre-school examinations. Collected data will be analyzed and compared to national and international surveys, evaluating the trends of the children's height and weight development. Weight status will be assessed by calculating z-BMI standardized for age and compared with national and international growth charts using both national and WHO classification. Potential interrelation between weight-status, weight development with cognitive performance will be explored.

The study will be able to deliver valuable insights in regards to the health of school children in the Rhein-Neckar Region as well as evaluate the effect of COVID-19 related lockdowns on their health.

Eligibility Criteria:
Inclusion Criteria:

* Written consent from parents and or guardians

Exclusion Criteria:

* Missing consent of parents or guardians
Mobile Attentional Bias Modification Training in Pediatric MS

This study will examine the feasibility of using a mobile ABMT application as a treatment modality in the Pediatric Multiple Sclerosis population. Participants will be asked to undergo one hour-long baseline evaluation, followed by at-home ABMT application sessions. Subjects will complete online REDCap or MyCap surveys weekly and at the end of the study.


Eligibility Criteria:
Inclusion Criteria:

* Age 12-24 years
* Confirmed Diagnosis of Multiple Sclerosis with onset \< 17 years and 11 months (defined by the 2013 International Pediatric MS Study Group (IPMSSG) criteria (Krupp, Tardieu, Amato, Banwell, Chitnis, Dale, Ghezzi, Hintzen, Kornberg, Pohl, Rostasy, Tenembaum, Wassmer, \& Sclerosis, 2013) and the 2010 McDonald criteria (Polman et al., 2011).)
* Followed at NYU Multiple Sclerosis Comprehensive Care Center
* Access to a mobile device with iOS (devices will be provided to subjects if this criteria is not met, see section 4.4)
* Active or concurrently enrolled in the ongoing US Network of Pediatric MS Centers Study Consortium

Exclusion Criteria:

* Previous report of an IQ \< 70
* Wide-Range Achievement Test-Fourth Edition (Wilkerson, 2006) Reading Subtest standard score \<85
* Non-English speaking, learned English in the past three years, or learned English after the age of 12 years
* Not willing to comply with all study procedures
* Insufficient visual and motor ability to operate the intervention and assessments
EFFICACY OF THE SLEEVE GASTROPLASTY WITH THE ENDOSCOPIC SYSTEM OVERSTICH SX ON WEIGHT LOSS AND REDUCTION OF CO-MORBIDITY FOR OBESE PATIENTS

The OverStitch ™ Sx System (Apollo Endosurgery Inc., Austin, Tx, Usa) is a new generation of endoscopic suturing device. It is inserted into an endoscope allowing the approximation of Luc Karsentys soft tissue by placement of sutures. It is as effective a suture system as a surgical system. The OverStitch ™ Sx allows suturing in the upper and lower GI with a flexible single channel endoscope. Previously, the ™ Overstich was only compatible with an Olympus dual channel endoscope.

Thus, a wide range of interventions are possible, including gastric endoplastic sleeve (ESG), RYGB revision, anastomotic fistula repair and / or sleeve revision. In each of these indications, the OverStitch (OverStitch) ™ system has shown its effectiveness and safety.

The OverStitch Endoscopic ™ Suture System allows the entire digestive wall to be sutured through a flexible endoscope. Thus, a wide range of interventions are possible, including gastric pocket repair after gastric bypass surgery, anastomotic fistula repair, endoscopic treatment of digestive perforation, and endoscopic sleeve surgery. In each of these indications, the OverStitch system has demonstrated its effectiveness and safety. But this technique is recent, especially in France. In addition, no data has yet been released regarding the new Overstitch ™ Sx device compatible with all single channel endoscopes.

An observational study including patients in French centers that are experts in therapeutic endoscopy seems essential to us to better assess this new device and this new technique in practice


Eligibility Criteria:
Inclusion Criteria:

* Patient over 18, male or female
* Patient with obesity with a BMI\> 30 or BMI\> 40 (if surgery contraindicated or refused by the patient)
* Patient with a weight gain after sleeve gastroplasty or sleeve gastrectomy
* Informed and written consent of the patient obtained
* Complete clinical examination
* Lack of participation in another clinical study
* Patient able to follow, understand the study and answer the questionnaire

Exclusion Criteria:

* Haemorrhagic disease, haemostasis and coagulation disorder and platelets \<60000 / mm3).
* Breastfeeding women
* Toxicomany, alcoolism
* Patient known for gastric lesion requiring surveillance or familial history of gastric neoplasia
* Hiatus hernia\> 4 cm high
Outcomes of Surgical Treatment of Patients With Spinal Metastasis in AUH

To analyze the outcomes of surgical treatment of patients with spinal metastases in spine unit in AUH regarding the pain control, neurological status and ambulatory status as well as survival rate .

this study monitor what is the results after operative treatment of patients which have secondary metastases in spinal column concerning quality of live for one year and pain and neurology

Eligibility Criteria:
Inclusion Criteria:

* Patients \> 18 years old
* Patient with tissue proven dx of cancer

Exclusion Criteria:

* Patient younger 18 years old
* CNS or spinal 1ry tumor
ADVATE Post Authorization Safety Surveillance

The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* Subject has moderate or severe hemophilia A (baseline FVIII less than or equal to 5%)
* Subject currently has no measurable FVIII inhibitor titer greater than or equal to 1 BU (Bethesda or Nijmegen method)
* Subject has been prescribed ADVATE by their treating physician
* Subject may be of any age
* Subject or parent/legally authorized representative has provided written informed consent

Exclusion Criteria:

* None
Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes

This trial hopes to prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity in pregnant women with pre-labor premature rupture of the membranes.

This is a multicenter randomized double blinded trial that hopes to prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity including respiratory distress syndrome in pregnant women with a singleton gestation between 24w0d - 32w6d gestation who have documented premature rupture of the membranes.

Eligibility Criteria:
Inclusion Criteria:

* Participants age 18 years or older
* 24w0d to 32w6d weeks gestation
* Singleton pregnancy
* Received first course of ACS at or prior to 31w6d gestation
* Began first course of ACS at least 7 days ( =/\> 168 hours) prior to randomization
* Expectant management planned
* Premature Ruptured membranes (PROM) before onset of labor

Exclusion Criteria:

* Known major fetal anomalies
* Multiple gestation
* Not a candidate for expectant management
* Clinical chorioamnionitis (two or more of the following: temperature \> 38.0 degrees centigrade; uterine tenderness; foul smelling vaginal discharge or amniotic fluid; maternal tachycardia \>100 bpm; fetal tachycardia \>160 bpm; maternal White Blood Cell (WBC) count \>20 X 109/L; C-Reactive Protein (CRP) \> 5.9
* Already receiving corticosteroids for another condition
* Any contraindications to the maternal use of corticosteroids
Evaluation of a Decision Support Tool

Investigators will conduct a randomized trial with patients, through one-on-one interviews, to evaluate their understanding of and willingness to use a decision support tool and to determine if receiving and discussing the decision support tool improves the likelihood that a patient is adherent to a new antihypertensive medication.


Eligibility Criteria:
Inclusion Criteria:

* does not pick up a prescription for a new antihypertensive medication within 14 days as identified by CVS pharmacy, their retail pharmacy provider.
* High blood pressure diagnosis

Exclusion Criteria:

* under age 25.
Incidence, Clinical Characteristics and Prognosis of Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Spontaneous Coronary Reperfusion in the Modern Antithrombotic Strategy Area

The rapid and complete restoration of coronary flow is a key issue in the management of STEMI. Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy associated with antithrombotic drugs.

In daily practice, it is not rare that some patients may achieve reopening of the culprit artery without undergoing any mechanical reperfusion therapy, which is called " spontaneous reperfusion ". The latter is associated with improved outcomes in several studies but none of these studies were done in the modern antithrombotic strategy area including new P2Y12 inhibitors. The aim of this study is to report the incidence, characteristics and outcomes of consecutive patients with STEMI admitted for coronary angiography with angiographic clinical evidence of spontaneous reperfusion in the modern medical antithrombotic strategy associated with primary PCI.


Eligibility Criteria:
Inclusion criteria:

* Older than 18 years old.
* patients with ongoing (within 12 hours after onset of symptoms) STEMI admitted for coronary angiography and receiving preloading dose of aspirin, heparin and P2Y12 inhibitor

Exclusion criteria:

* Patients with thrombolysis treatment before angiography
* Patients with cardiac arrest without ST-segment elevation on ECG after resuscitation
* Patients with myocardial infarction outside of acute phase (pain lasting more 12 hours)
* Patients with mental disease
* Patients not living in France
A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season

The study was designed to evaluate the pattern of seasonal allergic signs and symptoms consistent with ongoing ocular allergic inflammation during ragweed season. It was hypothesized that a pattern of ongoing ocular allergic inflammation existed in certain subjects.

Subjects who had a positive skin test to ragweed within 24 months of Visit 1 were instructed to complete a diary, which assessed their allergic signs and symptoms 3 times a day for 4 weeks. During the in-office visits, subjects were asked to completed a quality of life questionnaire, as well as a retrospective and/or prospective eye allergy questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* Subjects must:

  1. be willing and able to read, sign, and date the informed consent and HIPAA documents prior to initiation of Visit 1 procedures or exams;
  2. be at least 18 years of age;
  3. be willing to avoid disallowed medication, such as anti-allergy therapies
  4. have a positive history of ocular allergies and a positive skin test reaction to ragweed within the past 24 months;
  5. have a calculated logMAR visual acuity score using the ETDRS Chart of 0.60 or better in each eye at Visit 1;

Exclusion Criteria:

* Subjects may not:

  1. have preauricular lymphadenopathy or any ocular condition that could affect study parameters (particularly, clinically significant blepharitis, follicular conjunctivitis and iritis);
  2. have had any ocular infection within the last 30 days;
  3. have a positive diagnosis of moderate to severe dry eye syndrome (i.e., requiring daily use of artificial tears);
  4. wear contact lenses to each office visit; Note: Subjects will be allowed to use cold compresses.
Improving Laboratory Follow-up by Delivering an Enhanced Medication List to Outpatient Physician Practices

The investigators plan to develop a process to create an Enhanced Medication List. The INPC (Indiana Network for Patient Care) already obtains histories of medications dispensed by pharmacies from several sources: pharmacy benefit managers, RxHub, insurance companies, Medicaid, SureScripts, Wishard Health Services. The investigators will collect all the medication data available through the INPC for an individual patient. The investigators will enhance this medication list by including medication categories, improving the structure and appearance, displaying results of relevant laboratory tests, and adding decision support reminders. The investigators will test the value of such an "Enhanced Medication List" by providing it to outpatient physician practices (through the DOCS4DOCS clinical messaging service, or as a fax), preferably on the day that the patient has an office visit with the physician. The investigators will determine whether this intervention improves patient care: whether there are higher rates of recommended laboratory follow-up monitoring as a result; whether there are lower rates of harmful drug-drug interactions. The investigators will also seek the opinions of physicians regarding the benefit of this intervention.


Eligibility Criteria:
Inclusion Criteria:

* outpatient clinic patient visits

Exclusion Criteria:

* Age 18 and under
Laparoscopically Assisted Anorectal Pull-through Versus Posterior Sagittal Anorectoplasty

Anorectal malformations are congenital malformations, in which the terminal part of the hindgut is abnormally placed and lies outside (partially or completely) the sphincter mechanism.

The incidence of anorectal malformation \~1 in 5,000 More common in Down's syndrome and Cat-eye syndrome. Male \>female (60:40).It is classified into many types according to the degree of descent of the rectal pouch in the pelvis, the fistula between the rectum and the urinary system in males and genital system in females. The most common type in males is high anorectal malformation with rectourethral fistula

There are many historical operations for the management of the high type, but the most popular operation now is the posterior sagittal anorectoplasty which was published for the first time in 1982. Children undergoing posterior sagittal anorectoplasty may have lifelong bowel management problems of constipation, incontinence, and encopresis.

After the introduction of laparoscopy in pediatric surgery, many surgeons hope that the use of laparoscopy instead of posterior sagittal anorectoplasty may reduce the complications of the complications of the big incision and disturbance of sphincter mechanism which occur in posterior sagittal anorectoplasty operation. In addition to its role in diagnosis in complex anomalies like cloaca which is well established now. So the question is to what extent can the laparoscopy replace usual surgery for anorectal malformation.

Eligibility Criteria:
Inclusion Criteria:

-all male and female childs aged from 6 months to the age of 3 years, in assiut university hospital, who have been diagnosed to have high anorectal malformation since birth and for whom colostomy was done

Exclusion Criteria:

* all cases with low anomalies will be excluded.
* Female child with vestibular anus
* case with short distal pouch